ECHELON-1 trial data from ASH 2017: controversies and clinical translation

Brentuximab vedotin in treatment naïve cHL patients: a 5-year update of the ECHELON-1 trialПодробнее

Results of ECHELON-1 study for Hodgkin LymphomaПодробнее

ECHELON-1 Trial: Significance in Hodgkin LymphomaПодробнее

Updates from the ECHELON-1 studyПодробнее

Joseph Connors, MD: Bleomycin or Brentuximab Vedotin in Hodgkin Lymphoma?Подробнее

Dr. Kaplan on the Phase III ECHELON-1 Trial in Hodgkin LymphomaПодробнее

Updated 3-Year Findings of ECHELON-1 Trial Presented for Classical Hodgkin LymphomaПодробнее

ASH 2017: Improved Outcomes for Patients with Hodgkin Lymphoma from the Echelon-1 StudyПодробнее

ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lymphomaПодробнее

Upcoming amyloidosis clinical trial data to look forward to at ASH 2017Подробнее

The ECHELON-2 Trial Presented at ASH 2018Подробнее

Hodgkin Lymphoma: ECHELON-1 Update from ASCO 2022Подробнее

Overview of ECHELON-1 Study for Hodgkin LymphomaПодробнее

Dr. Ramchandren on the North American Results of the ECHELON-1 Study in Hodgkin LymphomaПодробнее

ECHELON-1 trial updates: overall survival dataПодробнее

ECHELON 1 Improves survival | Does the trial add up? | V Prasad investigates for Plenary SessionПодробнее

Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 studyПодробнее

Martin Hutchings, MD, considers how the ECHELON-1 study could be practice changingПодробнее